The effects of peroxisome proliferator-activated receptor gamma (PPARγ) in lipid metabolism, adipocyte differentiation, and apoptosis have been shown to be augmented by MYC inhibition, resulting in more well-differentiated phenotypes in both prostatic carcinoma and other neoplasms [48,49,50]. Here, PPARG is linked to neoplasm.